Ana sayfa
Piyasalar
Grafikler ve fikirler
Algo
Haberler
Store
Aracı kurumlar
İndir
Ekonomik Takvim
Alım-satım sinyalleri
Web Terminali
Arama yapmak için
/
tuşuna basın: @kullanıcı, $sembol, ...
Ara
Giriş yap
Hesap oluştur
Deutsch
English
Русский
中文
Español
Português
日本語
한국어
Français
Italiano
Türkçe
RYTM
#1011
Rhythm Pharmaceuticals, Inc. Common Stock
92.730
0
-4.28%
Sektör:
Baz:
Kar para birimi:
Günlük aralık
Yıllık aralık
Günlük değişim
-4.28%
Aylık değişim
-11.82%
6 aylık değişim
-15.94%
Yıllık değişim
-15.94%
Önceki kapanış
96.880
0
Open
92.830
0
Bid
Ask
Low
92.730
0
High
92.830
0
Hacim
161
Piyasalar
ABD hisse senetleri
Sağlık hizmetleri
RYTM
Open full chart
Financials
Overview
Rapor
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
50.18 M
50.33 M
56.75 M
60.14 M
63.22 M
68.29 M
—
Valuation ratios
Enterprise value
1.39 B
443.04 M
1.5 B
2.65 B
3.45 B
7.25 B
21.27 B
Price to earnings ratio
—
-7.13
-8.25
-14.1
-12.9
-34.42
-107.08
Price to sales ratio
—
156.95
63.15
33.62
26.24
—
—
Price to cash flow ratio
—
3.39
8.61
19.12
29.98
60.13
184.39
Price to book ratio
—
1.74
5.65
15.33
157.14
50.02
179.92
Enterprise value to EBITDA ratio
—
-2.61
-8.19
-13.05
-11.72
—
—
Profitability ratios
Return on assets %
0.72
0.21
0.47
0.56
0.66
0.41
0.46
Return on equity %
0.8
0.24
0.69
1.09
11.99
1.41
7.23
Return on invested capital %
11.27 K
4 279.65
3 215.48
2 584.26
2 491.51
1 914.72
1 057.99
Gross margin %
—
81.01
90.98
87.99
89.73
89.73
358.31
Operating margin %
—
5 391.85
757.92
238.1
204.04
101.19
421.96
EBITDA margin %
—
-5 376.82
-773.17
-262.61
-226.26
-127
—
Net margin %
—
2 207.1
766.22
238.52
200.27
103.57
433.6
Liquidity ratios
Quick ratio
—
7.1
8.83
5.43
3.08
4.16
14.47
Current ratio
10.1
7.1
8.9
5.58
3.24
4.41
15.24
Inventory turnover
—
5.4
1.41
1.61
0.98
0.88
0.95
Asset turnover
0
0.01
0.07
0.22
0.36
0.43
0.44
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
0.28
0.21
0.98
Long term debt to total equity ratio
—
—
—
—
4.98
0.73
16.02
Per share metrics
Operating cash flow per share
—
2.94
3.33
2.36
1.87
1.78
1.8
EBIT per share
—
-3.44
-3.52
-3.54
-4.84
-3.72
-2.98
EBITDA per share
—
-3.42
-3.51
-3.53
-4.83
-3.71
—
Total debt per share
—
—
—
—
—
—
—
Cash per share
—
5.94
6.39
4.78
5.26
5.98
21.82
Net current asset value per share
—
6.22
6.8
5.35
6.13
7.19
26.17
Tangible book value per share
—
5.63
4.92
2.82
0.26
2.06
4.52
Working capital per share
—
5.34
6.03
4.39
4.24
5.55
19.16
Book value per share
—
5.73
5.07
2.94
0.36
2.14
4.87
Haberler
Rhythm Pharmaceuticals: Guggenheim hebt Kursziel nach Unternehmensprognose an
Guggenheim raises Rhythm Pharmaceuticals stock price target on guidance
Citizens hebt Kursziel für Rhythm Pharmaceuticals wegen Zulassungsaussichten an
Citizens raises Rhythm Pharmaceuticals stock price target on HO approval outlook
Stifel bekräftigt Kaufempfehlung für Rhythm Pharmaceuticals mit Kursziel 131 $
Stifel reiterates Buy on Rhythm Pharmaceuticals stock, $131 target
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Beats Revenue Estimates
Rhythm Pharma Q4 2025: Umsatz übertrifft Erwartungen vor wichtiger Markteinführung
Rhythm Pharma Q4 2025 slides: revenue beats as HO launch nears
Rhythm Pharma: EPS übertrifft Schätzungen um 0,09 $ - Umsatz besser als erwartet
Rhythm Pharma earnings beat by $0.09, revenue topped estimates
Rhythm Pharma: Quartalszahlen im Fokus vor wichtiger Adipositas-Zulassung